These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan. Matsui Y; Nishiyama H; Watanabe J; Teramukai S; Ono Y; Ohshima S; Fujimoto K; Hirao Y; Fukushima M; Ogawa O Int J Clin Oncol; 2005 Apr; 10(2):133-8. PubMed ID: 15864700 [TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant immunochemotherapy in the treatment of nonmetastatic muscle-invasive bladder cancer: a systematic review. Sarkis J; Vannier E; Mjaess G; Pochet C; Albisinni S; Quackels T; Roumeguère T Immunotherapy; 2022 Dec; 14(17):1407-1417. PubMed ID: 36448639 [TBL] [Abstract][Full Text] [Related]
30. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001 [TBL] [Abstract][Full Text] [Related]
31. Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. Benkhadra R; Nayfeh T; Patibandla SK; Peterson C; Prokop L; Alhalabi O; Murad MH; Mao SS Bladder Cancer; 2022; 8(1):5-17. PubMed ID: 38994516 [TBL] [Abstract][Full Text] [Related]
32. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. Thibault C; Elaidi R; Vano YA; Rouabah M; Braychenko E; Helali I; Audenet F; Oudard S Bull Cancer; 2020 Jun; 107(5S):eS8-eS15. PubMed ID: 32620213 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer. Narayan V; Vaughn D Expert Opin Drug Metab Toxicol; 2015 May; 11(5):731-42. PubMed ID: 25604887 [TBL] [Abstract][Full Text] [Related]
34. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065 [TBL] [Abstract][Full Text] [Related]
35. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. McConkey DJ; Choi W; Shen Y; Lee IL; Porten S; Matin SF; Kamat AM; Corn P; Millikan RE; Dinney C; Czerniak B; Siefker-Radtke AO Eur Urol; 2016 May; 69(5):855-62. PubMed ID: 26343003 [TBL] [Abstract][Full Text] [Related]
36. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998 [TBL] [Abstract][Full Text] [Related]
37. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]. Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M; Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925 [TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer. Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093 [TBL] [Abstract][Full Text] [Related]
39. Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis. Li G; Niu HM; Wu HT; Lei BY; Wang XH; Guo XB; Feng SL Clin Invest Med; 2017 Apr; 40(2):E81-E94. PubMed ID: 28447581 [TBL] [Abstract][Full Text] [Related]
40. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer. Leibowitz-Amit R; Israel A; Gal M; Atenafu EA; Symon Z; Portnoy O; Laufer M; Dotan Z; Ramon J; Avni D; Fridman E; Berger R Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):790-796. PubMed ID: 27498850 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]